Artificial Intelligence in Life Sciences Global Market Report 2024

The artificial intelligence in life sciences market size has grown exponentially in recent years. It will grow from $2.35 billion in 2023 to $2.92 billion in 2024 at a compound annual growth rate (CAGR) of 24.2%. The growth observed during the historical period can be attributed to several factors, including the increasing number of clinical trials, a rising adoption of AI in the domain of research and development (R&D), and a heightened emphasis on the development of precision medicine and personalized drugs.

The artificial intelligence in life sciences market size is expected to see exponential growth in the next few years. It will grow to $6.82 billion in 2028 at a compound annual growth rate (CAGR) of 23.6%. The anticipated growth in the forecast period can be linked to various factors, including the escalating interest in real-time remote patient monitoring (RPM) systems, a growing demand for AI in drug discovery, and an increased adoption of AI in medical imaging analysis. Noteworthy trends expected in the forecast period encompass strategic partnerships, innovations in product offerings, technological advancements, increased investments, and ongoing research and development initiatives.

The growing interest in real-time remote patient monitoring (RPM) systems is set to drive the expansion of artificial intelligence in the life sciences market in the foreseeable future. Remote patient monitoring systems, characterized by technology-driven healthcare solutions, aim to monitor patients' health beyond traditional healthcare settings. In the life sciences domain, AI plays a pivotal role in remote patient monitoring, offering continuous, personalized, and data-driven insights that facilitate proactive healthcare management. A survey conducted by Vivalink, a US-based digital healthcare company, revealed a noteworthy surge in clinicians' adoption of remote patient monitoring (RPM), growing from 20% in 2021 to 81% in 2022, representing a substantial 305% increase. Consequently, the rising interest in real-time remote patient monitoring (RPM) systems is steering the growth of artificial intelligence in the life sciences market.

Leading companies operating in the artificial intelligence in the life sciences market are directing their efforts towards innovative products featuring technological advancements, exemplified by drug discovery software, to maintain their market standing. Drug discovery software comprises computer programs and applications tailored to assist researchers in the pharmaceutical and biotechnology sectors during the drug discovery process. In December 2023, Merck, a Germany-based science and technology company, unveiled AIDDISON, a revolutionary drug discovery software. Positioned as the first of its kind, AIDDISON integrates virtual molecule design with real-world manufacturability, leveraging generative AI, machine learning, and computer-aided drug design. AIDDISON excels in identifying drug candidates from a vast array of possibilities, considering essential properties such as non-toxicity and solubility. Its unique capability to bridge the gap between virtual molecule design and real-world manufacturability underscores a notable application of artificial intelligence in the life sciences sector.

In June 2023, Verix, a US-based company specializing in pharma commercial operations, completed the acquisition of Start-up.AI for an undisclosed sum. Verix's strategic move to acquire Start-up.AI aims to fortify its capabilities in artificial intelligence (AI) and machine learning (ML) within the pharmaceutical commercial operations sector. Start-up.ai, based in Israel, is a provider of an AI-driven commercial optimization platform, enhancing Verix's prowess in life science AI capabilities.

Major companies operating in the artificial intelligence in life sciences market report are Google LLC, Microsoft Corporation, Intel Corporation, IBM Corporation, Medtronic PLC, Nvidia Corporation, Novo Nordisk A/S, Siemens Healthineers AG, Philips Healthcare, Babylon Healthcare Services Ltd., Komodo Health Inc., Modernizing Medicine Inc., Viz.AI Inc., Butterfly Network Inc., Augmedix, AiCure LLC, HealthTap Inc., Welltok Inc., Enlitic Inc., PathAI Inc., Nano-X Imaging Ltd., Berg LLC, Insitro, Sense.ly Inc., Subtle Medical Inc., Medasense Biometrics Limited, Immunai, Atomwise Inc., Freenome Holdings Inc., CloudMedX Inc.

North America was the largest region in the Artificial Intelligence In Life Sciences market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the artificial intelligence in life sciences market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the artificial intelligence (AI) in the life sciences market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The artificial intelligence (AI) in the life sciences market consists of revenues earned by entities by private analytics, AI-driven clinical trial services, and real-world evidence services. The market value includes the value of related goods sold by the service provider or included within the service offering. The artificial intelligence (AI) in the life sciences market also consists of sales of high-performance computing (HPC) clusters, edge computing devices, and IoT devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

Artificial intelligence (AI) in life sciences involves the application of AI technologies and techniques across various domains within the life sciences industry. The integration of AI aims to enhance and expedite processes, improve decision-making, and extract valuable insights from complex data sets.

The primary components of artificial intelligence in life sciences include software, hardware, and services. The software employs AI algorithms to analyze extensive chemical databases, predicting the likelihood of specific molecules binding to target receptors, thereby accelerating the drug discovery process. These software applications can be deployed through on-premises and cloud-based models and find applications in various domains such as drug discovery, medical diagnosis, biotechnology, clinical trials, precision and personalized medicine, and patient monitoring.

The artificial intelligence in life sciences market research report is one of a series of new reports that provides artificial intelligence in life sciences market statistics, including artificial intelligence in life sciences industry global market size, regional shares, competitors with artificial intelligence in life sciences market share, detailed artificial intelligence in life science market segments, market trends, and opportunities, and any further data you may need to thrive in the artificial intelligence in life sciences industry. This artificial intelligence in life sciences market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.